SG11202008971VA - Compositions and methods for treating severe constipation - Google Patents
Compositions and methods for treating severe constipationInfo
- Publication number
- SG11202008971VA SG11202008971VA SG11202008971VA SG11202008971VA SG11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating severe
- severe constipation
- constipation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644033P | 2018-03-16 | 2018-03-16 | |
| PCT/US2019/022499 WO2019178492A1 (en) | 2018-03-16 | 2019-03-15 | Compositions and methods for treating severe constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008971VA true SG11202008971VA (en) | 2020-10-29 |
Family
ID=67904819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008971VA SG11202008971VA (en) | 2018-03-16 | 2019-03-15 | Compositions and methods for treating severe constipation |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11224590B2 (https=) |
| EP (1) | EP3765012B1 (https=) |
| JP (1) | JP7527984B2 (https=) |
| KR (1) | KR102747096B1 (https=) |
| CN (1) | CN111936137B (https=) |
| AU (1) | AU2019234956B2 (https=) |
| BR (1) | BR112020018790A2 (https=) |
| EA (1) | EA202092190A1 (https=) |
| FI (1) | FI3765012T3 (https=) |
| IL (1) | IL277332B2 (https=) |
| MX (1) | MX2020009604A (https=) |
| MY (1) | MY205335A (https=) |
| PE (1) | PE20210158A1 (https=) |
| PH (1) | PH12020551468A1 (https=) |
| SG (1) | SG11202008971VA (https=) |
| TW (1) | TWI704917B (https=) |
| WO (1) | WO2019178492A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL277332B2 (en) | 2018-03-16 | 2025-01-01 | Anji Pharmaceuticals Inc | Preparations and methods for treating severe constipation |
| KR20220052459A (ko) | 2020-10-21 | 2022-04-28 | 주식회사 엘지에너지솔루션 | 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3225997A (en) | 1996-05-30 | 1998-01-05 | Trustees Of Columbia University In The City Of New York, The | Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof |
| WO1999067268A1 (en) | 1998-06-24 | 1999-12-29 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US20030154504A1 (en) | 1998-06-24 | 2003-08-14 | Farese Robert V. | Methods and compositions for modulating carbohydrate metabolism |
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| JP2004502686A (ja) | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| US6444427B1 (en) | 2000-07-11 | 2002-09-03 | The Regents Of The University Of California | Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| EP1653969A4 (en) | 2003-08-07 | 2006-12-20 | Japan Tobacco Inc | PYRROLO 1,2-B PYRIDAZINE DERIVATIVES |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| JP2006045209A (ja) | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| JP2008516978A (ja) | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用 |
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| KR20080000652A (ko) | 2005-04-19 | 2008-01-02 | 바이엘 파마슈티칼스 코포레이션 | 아릴 알킬산 유도체 및 그의 용도 |
| WO2007002740A2 (en) | 2005-06-28 | 2007-01-04 | E. I. Du Pont De Nemours And Company | Buffer compositions |
| EP2402320A1 (en) * | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
| MA34097B1 (fr) * | 2010-03-30 | 2013-03-05 | Novartis Ag | Utilisations d'inhibiteurs de dgat1 |
| WO2011126967A1 (en) * | 2010-04-08 | 2011-10-13 | Medicinova, Inc. | Methods and compositions for the treatment of irritable bowel syndrome |
| AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| WO2013130370A2 (en) * | 2012-03-01 | 2013-09-06 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| CN104936581A (zh) * | 2012-08-29 | 2015-09-23 | 萨利克斯药品有限公司 | 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法 |
| US9895423B2 (en) * | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| IL277332B2 (en) | 2018-03-16 | 2025-01-01 | Anji Pharmaceuticals Inc | Preparations and methods for treating severe constipation |
-
2019
- 2019-03-15 IL IL277332A patent/IL277332B2/en unknown
- 2019-03-15 MX MX2020009604A patent/MX2020009604A/es unknown
- 2019-03-15 FI FIEP19767984.8T patent/FI3765012T3/fi active
- 2019-03-15 US US16/355,085 patent/US11224590B2/en active Active
- 2019-03-15 SG SG11202008971VA patent/SG11202008971VA/en unknown
- 2019-03-15 BR BR112020018790-9A patent/BR112020018790A2/pt active Search and Examination
- 2019-03-15 EP EP19767984.8A patent/EP3765012B1/en active Active
- 2019-03-15 EA EA202092190A patent/EA202092190A1/ru unknown
- 2019-03-15 PE PE2020001407A patent/PE20210158A1/es unknown
- 2019-03-15 MY MYPI2020004779A patent/MY205335A/en unknown
- 2019-03-15 WO PCT/US2019/022499 patent/WO2019178492A1/en not_active Ceased
- 2019-03-15 KR KR1020207029661A patent/KR102747096B1/ko active Active
- 2019-03-15 JP JP2020573085A patent/JP7527984B2/ja active Active
- 2019-03-15 CN CN201980019537.3A patent/CN111936137B/zh active Active
- 2019-03-15 AU AU2019234956A patent/AU2019234956B2/en active Active
- 2019-03-18 TW TW108109164A patent/TWI704917B/zh active
-
2020
- 2020-09-14 PH PH12020551468A patent/PH12020551468A1/en unknown
-
2021
- 2021-12-30 US US17/565,584 patent/US11819495B2/en active Active
-
2023
- 2023-10-11 US US18/378,976 patent/US12343334B2/en active Active
-
2025
- 2025-06-10 US US19/233,154 patent/US20260000651A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102747096B1 (ko) | 2024-12-26 |
| IL277332B1 (en) | 2024-09-01 |
| US20260000651A1 (en) | 2026-01-01 |
| CA3093970A1 (en) | 2019-09-19 |
| AU2019234956B2 (en) | 2025-01-30 |
| US11819495B2 (en) | 2023-11-21 |
| EP3765012B1 (en) | 2026-03-04 |
| MY205335A (en) | 2024-10-16 |
| JP2021518431A (ja) | 2021-08-02 |
| US20240293376A1 (en) | 2024-09-05 |
| WO2019178492A1 (en) | 2019-09-19 |
| PH12020551468A1 (en) | 2021-09-01 |
| BR112020018790A2 (pt) | 2020-10-13 |
| AU2019234956A1 (en) | 2020-10-01 |
| EP3765012A4 (en) | 2021-12-15 |
| IL277332A (en) | 2020-10-29 |
| IL277332B2 (en) | 2025-01-01 |
| US20220193044A1 (en) | 2022-06-23 |
| CN111936137A (zh) | 2020-11-13 |
| KR20200136428A (ko) | 2020-12-07 |
| EP3765012A1 (en) | 2021-01-20 |
| JP7527984B2 (ja) | 2024-08-05 |
| EA202092190A1 (ru) | 2020-11-19 |
| TWI704917B (zh) | 2020-09-21 |
| PE20210158A1 (es) | 2021-01-26 |
| TW201944995A (zh) | 2019-12-01 |
| MX2020009604A (es) | 2023-01-25 |
| US11224590B2 (en) | 2022-01-18 |
| US20190282549A1 (en) | 2019-09-19 |
| US12343334B2 (en) | 2025-07-01 |
| CN111936137B (zh) | 2023-09-08 |
| FI3765012T3 (fi) | 2026-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| IL274837A (en) | Methods and preparations for the treatment of cancer | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| IL325803A (en) | Materials and methods for cancer treatment | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| IL271256A (en) | Preparations and methods for the treatment of teopathy | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| PT3810128T (pt) | Composições para tratar e/ou prevenir doenças de agregação de proteinas | |
| SG11202103415WA (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
| EP3883588A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| EP3773585A4 (en) | Compositions and methods for treating cancer | |
| ZA202101360B (en) | Compositions and methods for treating the eye |